REGULATORY
MHLW Eyes 2 Year Transition for Electronic Data Submissions for New Drugs, Biosimilars
Japan’s health ministry plans to require drug makers to file patient-by-patient electronic data for their PII/PIII clinical studies when they seek regulatory approval for new drugs and biosimilars, beginning sometime in FY2016, but it will set a transition period of…
To read the full story
Related Article
- MHLW Issues Notification on Electronic Applications
June 24, 2014
REGULATORY
- US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
- CEA Review Group Holds First Meeting, Technical Debate Yet to Begin
May 26, 2026
- AstraZeneca’s Oral SERD, MSD RSV Antibody Clear Japan Panel Review
May 26, 2026
- Japan Mulls Target on “Social Security Burden Rate” after CEFP Call
May 25, 2026
- Ishin Deepens Debate on Healthcare Macroeconomic Indexing
May 25, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…





